A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, With an Optional 2-month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients
A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, With an Optional 2-month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients
The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients
Inclusion Criteria:
Exclusion Criteria:
Brentwood, TN, Chile
Brentwood, TN, Germany
Saint Laurent, QC, Hungary
Brentwood, TN, Latvia
Brentwood, TN, Lithuania
Monterrey, Mexico, Mexico
Brentwood, TN, Mexico
Meridas, Yucatán, Mexico
Chiuahua, Mexico
Brentwood, TN, Peru
Brentwood, TN, Poland
Tg Mures, Mureș County, Romania
Brentwood, TN, Romania
Brentwood, TN, Sweden
Saint Laurent, QC, United Kingdom
West Lothian, United Kingdom